Achieving Optimal Care of Necrotizing Soft-Tissue Infections (T)
This session has been identified and designated as Credit to Meet ACS Accreditation/Verification Requirements for Trauma.
This session will discuss clinical/laboratory predictors for patients at high risk of having an necrotizing soft-tissue infection (NSTI), and it will discuss surgical treatment and wound management, and the appropriate choice and duration of antimicrobial therapy after source control.
- Novel Approaches to Managing Patients with NSTI
Sharmila Dissanaike, MD, FACS, Lubbock, TX
- Antimicrobial Options in Managing NSTI
Addison K. May, MD, FACS, Nashville, TN
- Planning Reconstruction at the Time of Debridement
Kari A. Keys, MD, FACS, Seattle, WA
- NSTI: Challenging Cases
Eileen Bulger, MD
- Practicing surgeons
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
- For questions about the course content, please contact firstname.lastname@example.org.
- If you have any technical questions, contact email@example.com.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website: http://www.accme.org/requirements/accreditation-requirements-cme-providers/policies-and-definitions/financial-relationships-and-conflicts-interest
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures.)
Faculty and Disclosures
Sharmila Dissanaike, MD, FACS, Lubbock, TX - No Disclosures
Addison K. May, MD, FACS, Nashville, TN - Atox Bio, Ltd: Consulting Fees: Member of adjudication panel for randomized trial, Atox Bio, Ltd: VUMC has received research funding: VUMC site Principle investigator Fresenius Kabi: VUMC has received research funding: VUMC site Principle investigator
Kari A. Keys, MD, FACS, Seattle, WA - No Disclosures
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - No Disclosures
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - No Disclosures
David C. Borgstrom, MD, FACS, Morgantown, WV - No Disclosures
Daniel L. Dent, MD, FACS, San Antonio, TX - No Disclosures
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Audra A. Duncan, MD, FACS, London, ON - No Disclosures
Mariam F. Eskander, MD, Boston, MA - No Disclosures
Paula Ferrada, MD, FACS, Richmond, VA - No Disclosures
Neil H. Hyman, MD, FACS, Chicago, IL - No Disclosures
Martin S. Karpeh, Jr., MD, FACS, New York, NY - No Disclosures
Dennis H. Kraus, MD, FACS, New York, NY - No Disclosures
Kenneth W. Sharp, MD, FACS, Nashville, TN - No Disclosures
David A. Spain, MD, FACS, Stanford, CA - No Disclosures
Mary T. Hawn, MD, FACS, Stanford, CA - No Disclosures
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - No Disclosures
Barbara Lee Bass, MD, FACS, FRCS(Hon), Houston, TX - No Disclosures
Quan-Yang Duh, MD, FACS, San Francisco, CA - No Disclosures
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - No Disclosures
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - No Disclosures
Valerie W. Rusch, MD, FACS, New York, NY - No Disclosures
Note: Residents will receive a Certificate of Completion.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Certificate of Completion
- 1.50 Self Assessment Credit